Novel agents for resistant Gram-positive infections - A review

International Journal of Infectious Diseases

Volumn 6, Issue SUPPL. 1, 2002, Pages

  Strahilevitz, Jacob ^a   Rubinstein, Ethan ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; CLARITHROMYCIN; DAPTOMYCIN; EPEREZOLID; GLYCOPEPTIDE; LINEZOLID; MACROLIDE; METICILLIN; ORITAVANCIN; OXACILLIN; PENICILLIN G; TIGECYCLINE; VANCOMYCIN;

ANEMIA; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BONE DISEASE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG INDICATION; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HEADACHE; HOSPITAL INFECTION; HUMAN; LEUKOPENIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; PENICILLIN RESISTANCE; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTOPENIA; VANCOMYCIN RESISTANT ENTEROCOCCUS; DRUG EFFECT; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 0011851214     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(02)90153-0     Document Type: Review

References (78)

1. Brickner SJ, Hutchinson DK, Barbachyn MR et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem 1996; 39(3):673-679.
2. Cammarata SK, Timm JA, Hempsall KA, Todd WM, Oliphant TH, Hafkin B. Efficacy of linezolid in pneumonia due to penicillin intermediate and resistant Streptococcus pneumoniae. [abstract 80.010]. In: Programs and abstracts of the 9th International Congress on Infectious Diseases; Buenos Aires, Argentina, April 10-13, 2000. Boston: International Society of Infectious Diseases.
3. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42(12):3251-3255.
4. Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997; 41(10):2127-2131.
5. Jones RN, Johnson DM, Erwin ME. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother 1996; 40(3):720-726.
6. Zurenko GE, Yagi BH, Schaadt RD et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40(4):839-845.
7. Cercenado E, Garcia-Garrote F, Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother 2001; 47(1): 77-81.
8. Gemmell CG. Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J Antimicrob Chemother 2001; 48(1):47-52.
9. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycinintermediate and - resistant strains. Antimicrob Agents Chemother 2000; 44(4):1062-1066.
10. Wootton M, Howe RA, Walsh TR, Bennett PM, Macgowan AP. In-vitro activity of a range of old and new antimicrobials to hetero-vancomycin-intermediate Staphylococcus aureus (hVISA) [abstract 2313]. In: Program and abstract of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000: Toronto, Canada.
11. Jones RN, Pfaller MA, Erwin ME et al. Antimicrobial activity of linezolid tested against 3,808 strains of Gram-positive organisms having resistance to various drugs [abstract]. In: Program and abstract of the 37th Annual Meeting of the Infectious Disease Society of America; November 18-21, 1999; Philadelphia, PA.
12. Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999; 43(8):2059-2062.
13. Swaney SM, Shinabarger DL, Schaadt RD, Bock JH, Slightom JR, Zurenko GE. Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S rRNA [abstract C-104]. In: Programs and abstracts of the 38th International Conference of Antimicrobial Agents and Chemotherapy; September 26-29, 1998: San Diego, CA.
14. Zurenko GE, Todd WM, Hafkin B et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract 848]. In: Programs and abstracts of the 39th International Conference of Antimicrobial Agents and Chemotherapy; September 26-29, 1999: San Francisco, CA.
15. Linden P, Parkinson D, Pasculle AW, et al. Isolation of a vancomycin-resistant enterococcal strain with reduced susceptibility to linezolid [abstract 1105] In: Program and abstracts of 39th International Conference of Antimicrobial Agents and Chemotherapy; September 26-29, 1999: San Francisco, CA.
16. Pharmacia and Upjohn Company. Kalamazoo M USA. Linezolid prescribing information. http://www.zyvox.com/ utility/prescribing_info.htm
17. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357(9263):1179.
18. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358(9277):207-208.
19. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32(3):402-412.
20. Duvall SE, Bruss JB, McConnel-Martin MA et al. Comparison of oral linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: Results from a multinational phase III trial [abstract 80.005] In: Programs and abstracts of the 9th International Congress on Infectious Diseases; Buenos Aires, Argentina, April 10-13, 2000. Boston: International Society of Infectious Diseases.
21. Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44(12):3408-3413.
22. Leach TS, Kaja RW, Eckert SM, Schaser RJ, Todd WM, Hafkin B. Linezolid versus vancomycin for the treatment of MRSA infections: Results of a randomized phase III trial [abstract 95.079] In: Programs and abstracts of the 9th International Congress on Infectious Diseases; Buenos Aires, Argentina, April 10-13, 2000. Boston: International Society of Infectious Diseases.
23. Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(suppl. 2):S114-132.
24. Garrison MW, Rotschafer JC, Crossley KB. Suboptimal effect of daptomycin in the treatment of bacteremias. South Med J 1989; 82(11):1414-1415.
25. Canepari P, Boaretti M, del Mar Lleo M, Satta G. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother 1990; 34(6):1220-1226.
26. Alborn WE Jr, Allen NE, Preston DA. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35(11): 2282-2287.
27. Oliver NS, Laganas V, Bouchard M, Parr IB, Silverman JA. Structural basis for calcium dependence of the lipopeptide daptomycin [abstract C1-1800]. In: Programs and abstracts of the 41st International Conference of Antimicrobial Agents and Chemotherapy; September 22-25, 2001: Chicago, IL.
28. Sliverman JA, Perlmutter NG, Shapiro HM. Membrane depolarization and bactericidal activity are correlated for daptomycin [abstract C1-1800] In: Programs and abstracts of the 41st International Conference of Antimicrobial Agents and Chemotherapy; September 22-25, 2001: Chicago, IL.
29. Jones RN, Barry AL. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother 1987; 31(4):625-629.
30. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001; 45(6):1919-1922.
31. King A, Phillips I. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother 2001; 48(2):219-223.
32. Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000; 44(12):3447-3450.
33. Liebowitz LD, Saunders J, Chalkley LJ, Koornhof HJ. In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide. Antimicrob Agents Chemother 1988; 32(1);24-246.
34. Mouton RP, Mulders SL. LY146032: activity and resistance development in vitro. J Antimicrob Chemother 1987; 20(4):513-517.
35. Cantoni L, Glauser MP, Bille J. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother 1990;34(12):2348-53.
36. Kennedy S, Chambers HF. Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob Agents Chemother 1989; 33(9):1522-1525.
37. Luu QN, Buxton TB, Nelson DR, Rissing JP. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur J Clin Microbiol Infect Dis 1989; 8(6):562-563.
38. Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44(11):2948-2953.
39. Cubist: http://www.cubist.com/site/html/product_main.html
40. Tally FP, Berman C, Oleson FB, DeBruin MF. Daptomycin treatment of serious gram-positive infections [abstract WeP233]. Clinical Microbiology and Infection 2000; 6(suppl. 1):135.
41. Rybak MJ, Bailey EM, Lamp KC, Kaatz GW. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother 1992; 36(5):1109-1114.
42. Sakoulas G, Eliopoulus GM, Alder J, Moellering Jr RC. Daptomycin in experimental endocarditis due to methicillin resistant Staphylococcus aureus [abstract B-785] In: Programs and abstracts of the 41st International Conference of Antimicrobial Agents and Chemotherapy; September 22-25, 2001: Chicago, IL.
43. Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections. J Antimicrob Chemother 2000; 46(4):523-526.
44. Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 1999; 9(10):1459-1462.
45. Standiford HC. Tetracyclines and Chloramphenicol. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and practice of infectious diseases, 5th ed. 2000; 336-348. London: Churchill Livingstone.
46. Deshpande LM, Gales AC, Jones RN. GAR-936 (9-t-butylglycylamido- minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Int J Antimicrob Agents 2001; 18(1):29-35.
47. Bergeron J, Ammirati M, Danley D et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996; 40(9): 2226-2228.
48. Someya Y, Yamaguchi A, Sawai T. A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter. Antimicrob Agents Chemother 1995; 39(1): 247-249.
49. Hoellman DB, Pankuch GA, Jacobs MR, Appelbaum PC. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 2000; 44(4):1085-1088.
50. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000; 44(8):2225-2229.
51. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43(4):738-744.
52. Cercenado E, Gomez JA, Bouza E. In vitro activity of GAR-936, a novel glycylcycline, against vancomycin resistant enterococci, teicoplanin resistant coagulase negative staphylococci and vancomycin intermediate Staphylococcus aureus [abstract E-522]. In: Programs and abstracts of the 41st International Conference of Antimicrobial Agents and Chemotherapy; September 22-25, 2001: Chicago, IL.
53. van Ogtrop ML, Andes D, Stamstad TJ et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44(4):943-949.
54. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36(1):19-36.
55. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother 2000; 44(10): 2747-2751.
56. Whittington WL, Roberts MC, Hale J, Holmes KK. Susceptibilities of Neisseria gonorrhoeae to the glycylcyclines. Antimicrob Agents Chemother 1995; 39(8):1864-1865.
57. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000; 16(1):61-63.
58. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45(9): 2604-2608.
59. Tuckman M, Petersen PJ, Projan SJ. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb Drug Resist 2000; 6(4):277-282.
60. Fekety R. Vancomycin, teicoplanin, and the streptogramins: quinupristin and dalfopristin. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and practice of infectious diseases, 5th ed. 2000; 382-392. London: Churchill Livingstone.
61. Nicas TI, Mullen DL, Flokowitsch JE et al. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob Agents Chemother 1996; 40(9):2194-2199.
62. Allen NE, LeTourneau DL, Hobbs JN Jr. Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues. Antimicrob Agents Chemother 1997; 41(1):66-71.
63. Allen NE, Hobbs JN Jr, Nicas TI. Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and resistant bacteria by a semisynthetic glycopeptide antibiotic. Antimicrob Agents Chemother 1996; 40(10): 2356-2362.
64. Baltch AL, Smith RP, Ritz WJ, Bopp LH. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1998; 42(10): 2564-2568.
65. Zeckel ML, Preston DA, Allen BS. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study. Antimicrob Agents Chemother 2000; 44(5):1370-1374.
66. Garcia-Garrote F, Cercenado E, Alcala L, Bouza E. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates. Antimicrob Agents Chemother 1998; 42(9):2452-2455.
67. Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother 1997; 41(10):2165-2172.
68. Hershberger E, Aeschlimann JR, Moldovan T, Rybak MJ. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods. Antimicrob Agents Chemother 1999; 43(3):717-721.
69. Fraise AP, Andrews J, Wise R. Activity of a new glyco-peptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms. J Antimicrob Chemother 1997; 40(3):423-425.
70. Schouten MA, Voss A, Hoogkamp-Korstanje JA. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group. Antimicrob Agents Chemother 1999; 43(10): 2542-2546.
71. Cheron M, Boisivon A. In vitro bactericidal effect of LY 333328 against vancomycin resistant and susceptible E. faecium [abstract F-8]. In: Programs and abstracts of the 37th International Conference of Antimicrobial Agents and Chemotherapy; September 26-October 1 1997: Toronto, Ontario, Canada.
72. Fasola E, Spangler SK, Ednie LM, Jacobs MR, Bajaksouzian S, Appelbaum PC. Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996; 40(11):2661-2663.
73. Arthur M, Depardieu F, Reynolds P, Courvalin P. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother 1999; 43(8):1875-1880.
74. Struwig MC, Botha PL, Chalkley LJ. In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci. Antimicrob Agents Chemother 1998; 42(10):2752-2755.
75. Spencker FB, Gresens K, Rodloff AC. In vitro activity of linezolid, eperezolid, quinupristin/dalfopristin, and the new glycopeptide LY333328 against enterococci recovered from intensive care units and hematology-oncology wards of a German university hospital. [abstract E-1423]. In: Programs and abstracts of the 41st International Conference of Antimicrobial Agents and Chemotherapy; September 22-25 2001: Chicago, IL.
76. Hershberger E, Bozigar PS, Rybak MJ, Zervos MJ. Activity of daptomycin (D) compared to linezolid (L) against vancomycin resistant enterococci (VRE), methicillin resistant Staphylococcus aureus (MRSA), and glyco-peptide intermediate Staphylococcus aureus (GISA) in in vitro infection model. [abstract A-2075]. In: Programs and abstracts of the 41st International Conference of Antimicrobial Agents and Chemotherapy; September 22-25 2001: Chicago, IL.
77. Bryskier A. Novelties in the field of anti-infective compounds in 1999. Clin Infect Dis 2000; 31(6):1423-1466. Linden P, Parkinson D, Pasculle AW et al. Isolation of a vancomycin-resistant enterococcal strain with reduced susceptibility to linezolid [abstract 1105]. In: Programs and abstracts of the 39th International Conference of Antimicrobial Agents and Chemotherapy; September 26-29, 1999: San Francisco, CA.
78. Bryskier A. Novelties in the field of anti-infective compounds in 1999. Clin Infect Dis 2000; 31(6):1423-1466. Linden P, Parkinson D, Pasculle AW et al. Isolation of a vancomycin-resistant enterococcal strain with reduced susceptibility to linezolid [abstract 1105]. In: Programs and abstracts of the 39th International Conference of Antimicrobial Agents and Chemotherapy; September 26-29, 1999: San Francisco, CA.